The Resource MTOR inhibition for cancer therapy : past, present and future, edited by Monica Mita, Alain Mita, Eric K. Rowinsky

MTOR inhibition for cancer therapy : past, present and future, edited by Monica Mita, Alain Mita, Eric K. Rowinsky

Label
MTOR inhibition for cancer therapy : past, present and future
Title
MTOR inhibition for cancer therapy
Title remainder
past, present and future
Statement of responsibility
edited by Monica Mita, Alain Mita, Eric K. Rowinsky
Contributor
Editor
Subject
Language
eng
Summary
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation
Cataloging source
NUI
Dewey number
616.994
Illustrations
illustrations
Image bit depth
0
Index
no index present
LC call number
  • RC254-282
  • RC270.8
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
Label
MTOR inhibition for cancer therapy : past, present and future, edited by Monica Mita, Alain Mita, Eric K. Rowinsky
Publication
Antecedent source
mixed
Bibliography note
Includes bibliographical references
http://library.link/vocab/branchCode
  • net
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Color
not applicable
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors
Control code
ocn932167141
Dimensions
unknown
Extent
1 online resource (vi, 300 pages)
File format
multiple file formats
Form of item
online
Isbn
9782817804927
Level of compression
uncompressed
Media category
computer
Media MARC source
rdamedia
Media type code
c
Other control number
10.1007/978-2-8178-0492-7
Other physical details
illustrations (some color)
Quality assurance targets
absent
http://library.link/vocab/recordID
.b35315684
Reformatting quality
access
Specific material designation
remote
System control number
  • (OCoLC)932167141
  • springer2817804929

Library Locations

    • Deakin University Library - Geelong Waurn Ponds CampusBorrow it
      75 Pigdons Road, Waurn Ponds, Victoria, 3216, AU
      -38.195656 144.304955
Processing Feedback ...